Aileron Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015
Selling, General & Admin	11.36	9.68	9.6	9.33	12.29	13.45	8.77	7.89	5.06
Research & Development	3.99	17.97	17.01	11.17	17.66	18.45	14.24	10.28	7.83
Other Operating Expenses	0.93	0	0	0	0	0	0	0	0
Operating Expenses	16.28	27.65	26.61	20.5	29.96	31.9	23.01	18.17	12.89
Operating Income	-16.28	-27.65	-26.61	-20.5	-29.96	-31.9	-23.01	-18.17	-12.89
Other Expense / Income	-0.54	-0.32	-0.44	0.66	-0.59	-0.36	-0.4	-0.05	-0.01
Pretax Income	-15.73	-27.33	-26.16	-21.16	-29.37	-31.55	-22.6	-18.12	-12.88
Net Income	-15.73	-27.33	-26.16	-21.16	-29.37	-31.55	-22.6	-18.12	-12.88
Preferred Dividends	0	0	0	0	0	0	0.04	0.08	0.07
Net Income Common	-15.73	-27.33	-26.16	-21.16	-29.37	-31.55	-22.65	-18.2	-12.95
Shares Outstanding (Basic)	5	5	4	2	1	1	0	0	0
Shares Outstanding (Diluted)	5	5	4	2	1	1	0	0	0
Shares Change	1.31%	2.23%	154.70%	42.11%	66.48%	98.01%	1632.24%	7.23%	-
EPS (Basic)	-3.42	-6.02	-5.89	-12.20	-24.00	-42.80	-60.80	-847.00	-646.20
EPS (Diluted)	-3.42	-6.02	-5.89	-12.20	-24.00	-42.80	-60.80	-847.00	-646.20
Free Cash Flow	-19.77	-24.87	-23.85	-20.27	-26.63	-32.35	-20.67	-15.01	-11.8
Free Cash Flow Per Share	-4.30	-5.48	-5.37	-11.63	-21.70	-43.90	-55.55	-698.84	-589.15
EBITDA	-15.61	-27.16	-26.04	-20.99	-29.21	-31.33	-22.48	-17.89	-12.55
Depreciation & Amortization	0.12	0.17	0.12	0.16	0.16	0.22	0.13	0.23	0.33
EBIT	-15.73	-27.33	-26.16	-21.16	-29.37	-31.55	-22.6	-18.12	-12.88

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).